Developing a multiepitope vaccine for the prevention of SARS-CoV-2 and monkeypox virus co-infection: A reverse vaccinology analysis
International Immunopharmacology · 2023
DOI: 10.1016/j.intimp.2023.109728 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2023. Verfasst von Fan Jiang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Tuberculosis Prevention and Control Key Laboratory/Beijing Key Laboratory of New Techniques of Tuberculosis Diagnosis and Treatment, Senior Departmen…. Hauptthemen laut MEDLINE: Coinfection, COVID-19, Mpox, Monkeypox. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 116 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Beijing Municipal Science and Technology Commission, Key Technologies Research and Development Program, National Key Research and Development Program of China.
Abstract (Originalsprache)
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and monkeypox virus (MPXV) severely threaten human health; however, currently, no vaccine can prevent a co-infection with both viruses. METHODS: Five antigens were selected to predict dominant T and B cell epitopes screened for immunogenicity, antigenicity, toxicity, and sensitization. After screening, all antigens joined in the construction of a novel multiepitope vaccine. The physicochemical and immunological characteristics, and secondary and tertiary structures of the vaccine were predicted and analyzed using bio- and immunoinformatics. Finally, codon optimization and cloning in-silico were performed. RESULTS: A new multiepitope vaccine, named S7M8, was constructed based on four helper T lymphocyte (HTL) epitopes, six cytotoxic T lymphocyte (CTL) epitopes, five B cell epitopes, as well as Toll-like receptor (TLR) agonists. The antigenicity and immunogenicity scores of the S7M8 vaccine were 0.907374 and 0.6552, respectively. The S7M8 vaccine was comprised of 26.96% α-helices, the optimized Z-value of the tertiary structure was -5.92, and the favored area after majorization in the Ramachandran plot was 84.54%. Molecular docking showed that the S7M8 vaccine could tightly bind to TLR2 (-1100.6 kcal/mol) and TLR4 (-950.3 kcal/mol). In addition, the immune stimulation prediction indicated that the S7M8 vaccine could activate T and B lymphocytes to produce high levels of Th1 cytokines and antibodies. CONCLUSION: S7M8 is a promising biomarker with good antigenicity, immunogenicity, non-toxicity, and non-sensitization. The S7M8 vaccine can trigger significantly high levels of Th1 cytokines and antibodies and may be a potentially powerful tool in preventing SARS-CoV-2 and MPXV.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Tuberculosis Prevention and Control Key Laboratory/Beijing Key Laboratory of New Techniques of Tuberculosis Diagnosis and Treatment, Senior Department of Tuberculosis, The 8th Medical Center of PLA General Hospital, Bei…
- Department of Infectious Diseases, Tangdu Hospital, Air Force Medical University, Xi'an, China. Electronic address: lianjq@fmmu.edu.cn.
Förderung
- Beijing Municipal Science and Technology Commission
- Key Technologies Research and Development Program
- National Key Research and Development Program of China
Zitieren
APA
Jiang, F., Liu, Y., Xue, Y., Cheng, P., Wang, J., Lian, J., & Gong, W. (2023). Developing a multiepitope vaccine for the prevention of SARS-CoV-2 and monkeypox virus co-infection: A reverse vaccinology analysis. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.109728
Vancouver
Jiang F, Liu Y, Xue Y, Cheng P, Wang J, Lian J, et al. Developing a multiepitope vaccine for the prevention of SARS-CoV-2 and monkeypox virus co-infection: A reverse vaccinology analysis. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2023.109728
BibTeX
@article{Jiang2023,
author = {Jiang, Fan and Liu, Yinping and Xue, Yong and Cheng, Peng and Wang, Jie and Lian, Jianqi and Gong, Wenping},
title = {Developing a multiepitope vaccine for the prevention of SARS-CoV-2 and monkeypox virus co-infection: A reverse vaccinology analysis},
journal = {International Immunopharmacology},
year = {2023},
doi = {10.1016/j.intimp.2023.109728}
}
EUVIMED